Francesco Santullo1, Alberto Biondi2, Ferdinando C M Cananzi3, Valeria Fico4, Flavio Tirelli5, Riccardo Ricci6, Gianluca Rizzo7, Claudio Coco8, Claudio Mattana9, Domenico D'Ugo10, Roberto Persiani11. 1. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: francescosantullo@gmail.com. 2. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: biondi.alberto@tiscali.it. 3. Surgical Oncology Unit - Humanitas Clinical and Research Center, Rozzano, Italy. Electronic address: ferdinando.cananzi@cancercenter.humanitas.it. 4. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: valeriafico@hotmail.it. 5. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: tirelliflavio@gmail.com. 6. Department of Pathology, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: riccardo.ricci@unicatt.it. 7. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: gianluca.rizzo1979@libero.it. 8. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: claudio.coco@unicatt.it. 9. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: claudio.mattana@unicatt.it. 10. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: domenico.dugo@unicatt.it. 11. General Surgery Unit, Department of Surgery, "A. Gemelli" University Hospital, Catholic University of Rome, Rome, Italy. Electronic address: roberto.persiani@unicatt.it.
Abstract
BACKGROUND: The aim of this study was to identify stage II colon cancer patients with a high risk of recurrence. METHODS: All patients who underwent surgery for stage II colon cancer (CC) were retrospectively enrolled and sub-grouped according to TNM staging (IIa-b-c) and stage IIa in high (IIaHR) and low risk (IIaLR) according to pathologic features. The primary outcomes measured were the 5-year overall survival (OS) and disease-free survival (DFS). RESULTS: A total of 214 patients were reviewed. Only a maximum tumor diameter<4 cm in the IIaLR group was associated with a higher recurrence rate than a large tumor size (5-year DFS 71.7%vs.87.6%, p = 0.028). The DFS in the large IIaLR CC group was better than that in the IIaHR and IIb-c groups (5-year DFS: 92.7%vs.79.3%, p = 0.023). In contrast, the recurrence rate in the small IIaLR CC group was similar to that in the IIaHR, IIb-c stage CC group. CONCLUSIONS: In stage IIa CC evaluation of the tumor size as a prognostic factor may help identify patients who could benefit from additional postoperative therapy.
BACKGROUND: The aim of this study was to identify stage II colon cancerpatients with a high risk of recurrence. METHODS: All patients who underwent surgery for stage II colon cancer (CC) were retrospectively enrolled and sub-grouped according to TNM staging (IIa-b-c) and stage IIa in high (IIaHR) and low risk (IIaLR) according to pathologic features. The primary outcomes measured were the 5-year overall survival (OS) and disease-free survival (DFS). RESULTS: A total of 214 patients were reviewed. Only a maximum tumor diameter<4 cm in the IIaLR group was associated with a higher recurrence rate than a large tumor size (5-year DFS 71.7%vs.87.6%, p = 0.028). The DFS in the large IIaLR CC group was better than that in the IIaHR and IIb-c groups (5-year DFS: 92.7%vs.79.3%, p = 0.023). In contrast, the recurrence rate in the small IIaLR CC group was similar to that in the IIaHR, IIb-c stage CC group. CONCLUSIONS: In stage IIa CC evaluation of the tumor size as a prognostic factor may help identify patients who could benefit from additional postoperative therapy.